Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.39 |
| ▸ | USP2 | O75604 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21058874 | 0.97 | TSHR (0.42) | TSHRALDH1A1HSD17B10HPGDCYP1A2 | |
| SCHEMBL18912039 | 0.91 | TSHR (0.38) | TSHRALDH1A1HSD17B10HPGDCYP1A2 | |
| SCHEMBL3810524 | 0.84 | — | — | |
| SCHEMBL1753673 | 0.82 | CYP2D6 (0.41) | TSHRALDH1A1HSD17B10HPGDCYP1A2 | |
| Hydrochloric Acid SCHEMBL1298944 | 0.80 | TSHR (0.44) | TSHRALDH1A1HSD17B10HPGDCYP1A2 | |
| Hydrochloric Acid SCHEMBL27007071 | 0.80 | TSHR (0.44) | TSHRALDH1A1HSD17B10HPGDCYP1A2 | |
| SCHEMBL30105777 | 0.79 | — | — | |
| SCHEMBL7711019 | 0.79 | CYP2D6 (0.50) | TSHRALDH1A1HSD17B10HPGDCYP1A2 | |
| SCHEMBL16573817 | 0.78 | — | — | |
| SCHEMBL24717358 | 0.78 | CYP2D6 (0.36) | TSHRALDH1A1HSD17B10HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127254-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2022-04-28 | — | — | US | claimed |
| US-12606566-B2 | Substituted cyclopenta[4,5]pyrrolo[1,2-a]pyrazines as bruton's tyrosine kinase inhibitors | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) | 2026-04-21 | — | — | US | disclosed |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-25 | — | — | US | disclosed |
| WO-2025215579-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025151478-A1 | COMPOUNDS AND COMPOSITION FOR TARGETING TP53-Y220C MUTANTS | FLARE THERAPEUTICS INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025151549-A1 | PYRIDO[3,2-B]INDOLE-3-CARBONITRILE COMPOUNDS AND COMPOSITION FOR TARGETING TP53-Y220C MUTANTS | FLARE THERAPEUTICS INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20250223300-A1 | MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BETTA PHARMACEUTICALS CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4559920-A1 | MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2025-05-28 | — | — | EP | disclosed |
| CN-115715291-B | Bruton tyrosine kinase inhibitor and preparation method thereof | 上海华汇拓医药科技有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119522227-A | Macrocyclic compounds, pharmaceutical compositions and uses thereof | 贝达药业股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| WO-2009091856-A2 | BETA-LACTAMASE INHIBITORS | MERCK & CO., INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009053715-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| WO-2008152394-A1 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152387-A1 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152390-A1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008068265-A1 | NOVEL SUBSTITUTED DIAZA SPIRO PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
| EP-0417631-A2 | Condensed diazepinones, process for their preparation, and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606566-B2 | Substituted cyclopenta[4,5]pyrrolo[1,2-a]pyrazines as bruton's tyrosine kinase inhibitors | BTK, LYN, SYK | TSHR 710/4885ALDH1A1 4530/4885HSD17B10 3355/4885 |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | MCHR1, MCHR2, MC1R | TSHR 388/4885ALDH1A1 281/4885HSD17B10 484/4885 |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | TACR2, TACR3, NPY2R | TSHR 400/4885ALDH1A1 2836/4885HSD17B10 4106/4885 |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | ALK, TGFBR1, ACVR1 | TSHR 1137/4885ALDH1A1 742/4885HSD17B10 3973/4885 |
| US-20250223300-A1 | MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | EGFR, ERBB3, ERBB2 | TSHR 3065/4885ALDH1A1 3526/4885HSD17B10 1834/4885 |
| US-20220127254-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | KIT, TNNI3K, CILK1 | TSHR 3904/4885ALDH1A1 421/4885HSD17B10 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.